Related Experiment Video
Updated: Nov 18, 2025
Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Meningococcal vaccines in China
Yinghua Xu1, Yanan Li1, Shanshan Wang1
1Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes of Food and Drug Control, Beijing, People's Republic of China.
Abstract:
Meningococcal meningitis caused by Neisseria meningitidis is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s. Currently, there are polysaccharide, conjugate, and combined vaccine formulations against meningococcal meningitis in the Chinese market, almost all of which are produced by domestic manufacturers. It is necessary to further enhance national meningococcal surveillance to improve the level of prevention and control of meningococcus. However, the immune efficacy and persistence of immunity of vaccines should be monitored. More importantly, additional investments should be made to develop serogroup B meningococcal vaccines.
Insights
Meningococcal meningitis vaccination significantly reduced disease incidence in China since the 1980s. Enhanced surveillance and development of serogroup B vaccines are crucial for improved control.
Area of Science:
- Infectious Diseases
- Vaccinology
- Epidemiology
Background:
- Meningococcal meningitis, caused by *Neisseria meningitidis*, was a significant public health concern in China.
- The introduction of meningococcal vaccines in the 1980s led to a substantial decrease in disease incidence.
- Current vaccine market in China includes polysaccharide, conjugate, and combined formulations, primarily domestically produced.
Purpose of the Study:
- To highlight the impact of meningococcal vaccination on disease reduction in China.
- To emphasize the need for enhanced national surveillance of meningococcal disease.
- To advocate for further investment in the development of serogroup B meningococcal vaccines.
Main Methods:
- Review of historical disease incidence data before and after vaccine introduction.
- Analysis of the current vaccine landscape in China.
- Assessment of the need for improved surveillance and vaccine development.
Main Results:
- Meningococcal vaccination has markedly reduced the incidence of meningococcal meningitis.
- A range of meningococcal vaccines are available domestically in China.
- There is an ongoing need to monitor vaccine efficacy and duration of immunity.
Conclusions:
- Continued national surveillance is essential for effective meningococcal disease control.
- Monitoring the immune efficacy and persistence of existing vaccines is necessary.
- Development of serogroup B meningococcal vaccines requires increased investment and focus.
